ABOUT CENCORA PHARMALEX
Beginning in January 2024, companies in the PharmaLex family started a journey of rebranding aligned with Cencora, our parent company and a leading global pharmaceutical solutions organization centered on improving lives around the world.
PharmaLex adds to Cencora’s expanding suite of pharma solutions and serves the pharma, biotech, and medtech industries. We guide clients from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technology-elevated solutions to support clients through the entire product lifecycle.
View our content to discover how our expanded capabilities can help you – or contact a Cencora PharmaLex expert today with any questions.
TMF SOLUTIONS
Bring order, stability, and control to your TMF — our people make it happen.
CELL & GENE SOLUTIONS
Your therapy can make all the difference. Together, we'll unlock its potential.
PHARMACOVIGILANCE SOLUTIONS
Free your safety and clinical teams to focus on what matters most.
CONTACT INFORMATION
Cencora PharmaLex
1 W 1st Ave.
Conshohocken, PA 19428
UNITED STATES
FEATURED INSIGHTS
-
![GettyImages-2160140672-dashboard-laptop-data-charts-hand-coffee-cup]( "Exploring Payer Coverage Of Anti-Obesity Medications")
Understanding payer strategies for anti-obesity drugs is crucial. A recent study investigated commercial formulary trends, confirming cost as a major barrier despite positive patient outcomes.
-
![getty-1311598658-data-analytics]( "Exploring Value-Based Contracting In Rare Diseases")
How are payers using value-based contracts for costly rare disease therapies? Exploratory research sheds light on negotiation frequency, preferred contract types, and internal data management trends.
-
![GettyImages-697650898_medical data]( "5 Questions On Exploring Healthcare Decision-Maker Sentiments")
Research presented at AMCP 2025 uses natural language processing on decision-maker feedback to predict coverage. Learn about the surprising findings and next steps in this Q&A.
GET MORE DETAILS ON OUR SOLUTIONS
-
![GettyImages-836663414 medical team meeting]( "psiXchange: Intelligent, Automated Clinical Trial Safety Reporting Software")
Discover how intelligent, automated clinical trial safety reporting software can enhance compliance, reduce costs, and boost site responsiveness rates effortlessly.
-
![DNA digital health network (002)]( "Your Early \"Warning System\" To Assess Risks To TMF Health")
Introducing the TMF Health Score – an expert methodology that provides an “early warning system” to commonly overlooked issues that often lead to inspection findings.
-
![iStock-827581062-lab-computer]( "Phlexglobal Experts Fill The Gaps In eTMF Management")
Enable busy study teams to assess, prevent, and manage risk across the entire TMF spectrum – improving inspection-readiness with less effort.
-
![GettyImages-1130222213 timelines deadlines]( "Key Transition Timelines For Clinical Trials Regulation")
As deadlines loom for transitioning ongoing clinical trials in the EU to the Clinical Trials Regulation (CTR), understanding key timelines and dates becomes critical.
-
![GettyImages-1474723816 health files]( "How To Achieve Timely Migration Of Your TMF")
This precise, proven methodology delivers a high-quality migration of your Trial Master File to the destination system, typically just 4-6 weeks after receiving all documents from the source system.
-
![GettyImages-891264822 planning, meeting]( "The Benefits Of Engaging In Pre-Approval Information Exchange (PIE)")
Explore the top 3 insights on the impact of pre-approval communication and learn why healthcare decision makers want more pre-approval resources and engagement from manufacturers.
EXPLORE OUR THOUGHT LEADERSHIP
Explore the latest insights from the Cencora team.
WHITE PAPERS
-
![GettyImages-1026593952 tablet, data]( "Digital Innovation In Pharmacovigilance")
Digital Innovation In PharmacovigilanceExplore how AI can transform your pharmacovigilance efforts and enhance patient safety by leveraging the insights and decision framework outlined here.
-
![Medicine-pills-GettyImages-463594335]( "Mastering The Complexities Of Targeted Medicines")
Mastering The Complexities Of Targeted MedicinesExplore the challenges and strategies involved in developing targeted medicines, with insights into the complexities, collaborations, and considerations necessary for success.
-
![GettyImages-1016958284 biosimilar lab]( "20 Years Of Biosimilars: Are We On The Right Track?")
20 Years Of Biosimilars: Are We On The Right Track?Explore the transformative journey of biosimilars, 20 years in. Through industry expert insights collected from a recent panel discussion, explore regulatory hurdles, market shifts, and the path ahead.
PODCASTS
-
![Digital-marketing-GettyImages-1051659276]( "Navigating The Digital Era And Beyond For Engaging Key Decision Makers In Specialty Pharmacy")
Navigating The Digital Era And Beyond For Engaging Key Decision Makers In Specialty PharmacyTune in as experts discuss how biopharma companies can effectively engage healthcare decision-makers in the evolving digital landscape.
-
![Cencora - PharmaLex Talks 29]( "Exploring The Interactions Between Validation, Technology Transfer")
Exploring The Interactions Between Validation, Technology TransferListen as Gerardo Gomez delves into the intricate relationship between validation and technology transfer, taking into account the perspectives and standards set by regulators.
-
![Cencora - PharmaLex Talks 28]( "Early Access Programs: What They Are And How To Plan For Them")
Early Access Programs: What They Are And How To Plan For ThemExplore how early access programs are tailored to individual sufferers of rare, ultra-rare, or life-threatening conditions, as well as cohort programs, which target groups of patients afflicted with the same disease.
WEBINARS
-
![Cencora - estabished products webinar]( "Unlocking Continued Revenue And Growth From Established Products")
Unlocking Continued Revenue And Growth From Established ProductsGain insights into how pharmaceutical companies successfully handle post-approval regulatory upkeep for established products, focusing on reducing operational costs and expanding global market access.
-
![Driving Product Launch Success In Europe]( "Driving Product Launch Success In Europe")
Driving Product Launch Success In EuropeExplore key steps for preparing your medicinal product for the European market, including insights on challenges, timelines, and a success story.
-
![Brain AI Artificial intelligence-GettyImages-1582604385]( "Harnessing The Power Of AI In Health Evidence Generation Strategy")
Harnessing The Power Of AI In Health Evidence Generation StrategyExplore applications and limitations for artificial intelligence (AI) in healthcare as decision-makers determine whether to adopt the software in their environments.
E-BOOKS AND OTHER INSIGHTS
-
![GettyImages-1312272657 patient advocacy centricity]( "How Patient-Centric Approaches Are Shaping The Future Of CGT")
How Patient-Centric Approaches Are Shaping The Future Of CGTEmily Whitehead’s CAR-T cell therapy journey highlights the power of patient engagement in cell and gene therapies. Discover how her story and advocacy drive a patient-centric approach in innovative treatments.
-
![Cell culture pipette GettyImages-1173385629]( "A Comparative Guide To CGTs: Modalities, Landscape, And Logistics")
A Comparative Guide To CGTs: Modalities, Landscape, And LogisticsCell and gene therapies (CGTs) have the potential to revolutionize medicine. However, achieving therapeutic success requires advanced logistical consideration to ensure product safety and efficacy
-
![Scientist research laboratory pipette GettyImages-487041629]( "Overcoming The Complex Logistics Of Autologous Cell Therapy Trials: A Deep Dive Into Challenges And Solutions")
Overcoming The Complex Logistics Of Autologous Cell Therapy Trials: A Deep Dive Into Challenges And SolutionsExplore critical logistical requirements in autologous cell therapies logistics and learn how to overcome challenges and achieve successful and timely autologous cell therapy trials.
